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Introduction
As of December 31, 2015, 1621 laboratory-confirmed cases of Middle East respiratory 
syndrome coronavirus (MERS-CoV) had been reported to the World Health Organization 
(WHO), with 584 deaths in 26 countries (http://www.who.int/emergencies/mers-cov/en/). 
Two imported MERS-CoV cases were identified in the United States in May 2014.1 WHO 
has not declared this disease to constitute a Public Health Emergency of International 
Concern. However, sporadic MERS-CoV cases could continue to be imported into the 
United States. This article provides background information on MERS-CoV and MERS-
CoV infections in children for pediatric health care providers in the United States. MERS-
CoV infections among children have been reported, and severe respiratory illnesses have 
been documented in children with underlying conditions. United States health care providers 
should be vigilant in assessing children with severe respiratory illnesses and history of 
recent travel in or near the Arabian Peninsula for MERS-CoV infections.
Background on MERS-CoV
MERS-CoV was first identified in a patient who was hospitalized in Saudi Arabia in June 
2012. Since then, the majority of MERS-CoV cases have been identified in the Arabian 
Peninsula, but exported cases and outbreaks have been reported by other countries. 
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Dromedary camels, especially young camels, have been increasingly implicated as a 
potential source of MERS-CoV.2 MERS-CoV transmission from dromedary camels to 
humans is not well understood but may result from direct contact with camels. Person-to-
person MERS-CoV transmission most likely occurs via large respiratory droplets and close 
contact. Much of MERS-CoV person-to-person spread has occurred within health care 
facilities or, to a much lesser extent, within households.3 The mean incubation period has 
been estimated to be approximately 5 days, with a range of 2 to 14 days.4 The clinical 
spectrum varies from asymptomatic infection to pneumonia with respiratory distress. 
MERS-CoV has been identified in upper-respiratory-tract specimens collected from 
individuals with subclinical infection for up to 6 weeks.5 Typical signs and symptoms 
include fever, cough, and shortness of breath. MERS-CoV–infected patients with severe 
disease have generally been older adults or have had at least 1 underlying health condition.4 
Currently, there are no approved MERS-CoV therapeutics. Clinical management is focused 
on supportive care6 and implementation of infection prevention and control measures.7
What Is Known About MERS-CoV in Children?
Transmission
As of November 2015, at least 35 MERS-CoV cases in children (≤18 years) have been 
reported to WHO. The majority of reported pediatric MERS-CoV cases have been 
household contacts of adult cases, suggesting that acquisition of MERS-CoV infection in 
children is occurring in households.8 Clinicians and public health professionals should use 
caution when drawing conclusions from MERS-CoV surveillance data, which best captures 
occurrence of severe disease. Larger MERS-CoV outbreaks are often associated with adult 
hospital settings, limiting the opportunity for children to be exposed to MERS-CoV.
Manifestations
There are few clinical descriptions to inform clinicians about common presentations or signs 
and symptoms of MERS-CoV infection in children. A recent review of the literature by 
Thabet et al9 described 14 reported cases of MERS-CoV infection in children 9 months to 
16 years old; 9 cases were asymptomatic, and 5 exhibited symptoms. One additional 
symptomatic case occurred in the United Arab Emirates (UAE) in 2015.10 Of the 6 
symptomatic cases, 2 died. Reported signs and symptoms included fever (3), mild 
respiratory symptoms (3), and severe respiratory distress (2). Three of the 6 symptomatic 
cases had chest X-ray results reported; all 3 reported bilateral diffuse infiltrates. The 2 fatal 
pediatric MERS-CoV cases had comorbidities (infantile nephrotic syndrome and cystic 
fibrosis). A 14-year-old with Down syndrome and underlying cardiac disease required 
oxygen and survived. The 9 asymptomatic cases had no reported comorbidities.8
Considerations for the Pediatric Health Care Professional
MERS-CoV infection in children can range from asymptomatic infection to severe 
respiratory distress leading to death. Risk factors for MERS-CoV infection include travel to 
the Arabian Peninsula or other affected areas, contact with someone infected with MERS-
CoV, or presence in a facility with suspected cases of MERS-CoV within the past 14 days. 
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In children presenting with severe respiratory symptoms, especially for patients without a 
specific etiological diagnosis and those with underlying comorbidities, these risk factors 
should be considered. As seen in published reports, young children may not exhibit fever. In 
the United States, common detected pathogens in patients under investigation11 who were 
tested for MERS-CoV included influenza A and rhinovirus/enterovirus.12 As of January 
2016, MERS-CoV–affected countries include those in and around the Arabian Peninsula: 
Iran, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, the UAE, and Yemen. The 
Centers for Disease Control and Prevention (CDC) issues Health Alert Network (HAN) 
notifications informing clinicians of major outbreaks around the world, including MERS-
CoV, and will provide updates if new countries become affected. The HAN archive and 
subscription information is available at http://emergency.cdc.gov/han/. Clinicians should 
work diligently with public health departments to ensure timely notification of all suspected 
cases of MERS-CoV infection, so that proper testing of respiratory specimens at state health 
department laboratories can be performed, and all contacts can be identified and located 
quickly. If MERS-CoV is suspected, the patient should be isolated immediately, and 
recommended infection control precautions should be implemented. Guidance for health 
care workers on MERS-CoV patient and contact evaluation and management, including 
laboratory testing, infection control, and reporting, is available on CDC’s website at http://
www.cdc.gov/coronavirus/mers/interim-guidance.html. Balancing infection control 
precautions with family-centered care principles could be a challenge for pediatric health 
care providers, as it was during the SARS and Ebola outbreaks.13,14 Clinicians caring for 
confirmed MERS-CoV pediatric cases should also determine if such patients are eligible for 
any available investigational therapies through a clinical trial protocol.15
Conclusions
MERS-CoV infection can result in asymptomatic to severe and fatal illness, with more 
severe illness reported in children with underlying comorbidities. More epidemiological, 
clinical, immunological, and virological data are needed to understand MERS-CoV 
transmission to exposed children and optimal clinical management strategies. Pediatric 
health care providers must be vigilant in eliciting an epidemiological link to endemic areas 
and countries that are experiencing ongoing transmission, and identifying suspected cases of 
MERS-CoV in children can serve an important role in preventing additional cases by prompt 
reporting to public health authorities.
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